It is no longer the current profile. Read the canonical profile and its correction notice.
We added the July 2026 FDA advisory-committee meeting context and clarified that both the committee process and the selected trial record have limited implications. 14
What this version reported
FDA presented BPC-157 briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding and FDA's final determination remains pending; the cited trial registration also does not establish safety or effectiveness.↗↗↗
Trial records: NCT07437547
Sources for this version
- 1FDA briefing document for BPC-157-related bulk drug substances ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 2Certain bulk drug substances for use in compounding that may present significant safety risks ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
- 3BPC 157 for Acute Hamstring Muscle Strain Repair · record history version 1 · last update posted 2026-02-27 ↗
ClinicalTrials.gov · Official source · Source checked July 22, 2026
- 4July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026